Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$625.60+1.4%$680.43$603.47▼$1,211.20$68.39B0.27679,610 shs899,886 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals-2.72%-2.70%-11.70%-13.38%-36.35%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationREGNRegeneron Pharmaceuticals4.8202 of 5 stars4.43.01.72.33.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceREGNRegeneron Pharmaceuticals 2.76Moderate Buy$966.8854.55% UpsideCurrent Analyst Ratings BreakdownLatest REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$1,100.00 ➝ $1,000.002/5/2025REGNRegeneron PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/5/2025REGNRegeneron PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$940.00 ➝ $759.002/5/2025REGNRegeneron PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$762.00 ➝ $834.002/4/2025REGNRegeneron PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$980.00 ➝ $862.002/4/2025REGNRegeneron PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1,230.00 ➝ $1,030.002/4/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $903.002/4/2025REGNRegeneron PharmaceuticalsBernstein BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price Target$1,070.00 ➝ $1,000.001/28/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$795.00 ➝ $750.001/27/2025REGNRegeneron PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$1,195.00 ➝ $1,013.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookREGNRegeneron Pharmaceuticals$14.20B4.82$41.08 per share15.23$268.50 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateREGNRegeneron Pharmaceuticals$4.41B$38.2816.3416.452.3431.07%16.32%12.76%4/29/2025 (Estimated)Latest REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025N/AREGNRegeneron Pharmaceuticals$8.83N/AN/AN/A$3.40 billionN/A2/4/2025Q4 24REGNRegeneron Pharmaceuticals$11.21$12.07+$0.86$8.06$3.76 billion$3.79 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthREGNRegeneron Pharmaceuticals$0.880.14%N/A2.30%N/ALatest REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.53%2/20/20252/20/20253/20/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioREGNRegeneron Pharmaceuticals0.094.733.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipREGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipREGNRegeneron Pharmaceuticals7.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableREGNRegeneron Pharmaceuticals11,900109.33 million101.15 millionOptionableREGN HeadlinesRecent News About These CompaniesIs Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?April 2 at 10:30 AM | insidermonkey.comGroupama Asset Managment Has $56.45 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 2 at 7:06 AM | marketbeat.comTrexquant Investment LP Acquires 42,674 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 2 at 6:46 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Alliancebernstein L.P.April 2 at 5:33 AM | marketbeat.comSchroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 2 at 4:49 AM | marketbeat.comWINTON GROUP Ltd Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 2 at 4:07 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst DowngradeApril 1 at 11:12 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,000.00 at JPMorgan Chase & Co.April 1 at 10:56 AM | marketbeat.comRFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEOApril 1 at 10:02 AM | youtube.comFranklin Resources Inc. Has $1.46 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 1 at 7:09 AM | marketbeat.comCannell & Spears LLC Has $11.44 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 1 at 6:49 AM | marketbeat.comSummit Financial LLC Has $7.50 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 1 at 6:39 AM | marketbeat.comAIA Group Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)April 1 at 6:01 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,000.00 by Analysts at JPMorgan Chase & Co.April 1 at 2:39 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst DowngradeApril 1 at 1:23 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week LowsMarch 31 at 8:23 PM | finance.yahoo.comRegeneron price target lowered to $1,000 from $1,100 at JPMorganMarch 31 at 5:55 PM | markets.businessinsider.com3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy SpaceMarch 31 at 10:10 AM | zacks.comCalifornia Public Employees Retirement System Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)March 31 at 6:31 AM | marketbeat.comRWA Wealth Partners LLC Acquires 18,027 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)March 31 at 6:14 AM | marketbeat.comAllstate Corp Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)March 31 at 5:11 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN Company DescriptionsRegeneron Pharmaceuticals NASDAQ:REGN$625.60 +8.60 (+1.39%) Closing price 04:00 PM EasternExtended Trading$606.16 -19.44 (-3.11%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
